 | • レポートコード：GIR-23F3772 • 出版社/出版日：GlobalInfoResearch / 2023年2月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Central Nervous System Drugs Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界の中枢神経系用治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 中枢神経系用治療薬市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・OTC、Rxドラッグ アプリケーション別セグメントは次のように区分されます。 ・病院、薬局 世界の中枢神経系用治療薬市場の主要なマーケットプレーヤーは以下のとおりです。 ・Biogen、Pfizer、Teva、Novartis、Johnson & Johnson、EliLilly、Otsuka、Merck、AstraZeneca、Novartis、Takeda 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - 中枢神経系用治療薬の概要 - タイプ別分析（2017年vs2021年vs2028年）：OTC、Rxドラッグ - アプリケーション別分析（2017年vs2021年vs2028年）：病院、薬局 - 世界の中枢神経系用治療薬市場規模・予測 - 世界の中枢神経系用治療薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Biogen、Pfizer、Teva、Novartis、Johnson & Johnson、EliLilly、Otsuka、Merck、AstraZeneca、Novartis、Takeda ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：OTC、Rxドラッグ ・アプリケーション別分析2017年-2028年：病院、薬局 ・中枢神経系用治療薬の北米市場分析 - 中枢神経系用治療薬の北米市場：タイプ別市場規模2017年-2028年 - 中枢神経系用治療薬の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・中枢神経系用治療薬のヨーロッパ市場分析 - ：中枢神経系用治療薬のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：中枢神経系用治療薬のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・中枢神経系用治療薬のアジア太平洋市場分析 - 中枢神経系用治療薬のアジア太平洋市場：タイプ別市場規模2017年-2028年 - 中枢神経系用治療薬のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・中枢神経系用治療薬の南米市場分析 - 中枢神経系用治療薬の南米市場：タイプ別市場規模2017年-2028年 - 中枢神経系用治療薬の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・中枢神経系用治療薬の中東・アフリカ市場分析 - 中枢神経系用治療薬の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 中枢神経系用治療薬の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Central Nervous System Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Central Nervous System Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Central Nervous System Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While OTC segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Central Nervous System Drugs include Biogen, Pfizer, Teva, Novartis, and Johnson & Johnson, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Central Nervous System Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
OTC
Rx Drugs
Market segment by Application can be divided into
Hospital
Retail Pharmacy
The key market players for global Central Nervous System Drugs market are listed below:
Biogen
Pfizer
Teva
Novartis
Johnson & Johnson
EliLilly
Otsuka
Merck
AstraZeneca
Novartis
Takeda
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Central Nervous System Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Central Nervous System Drugs, with price, sales, revenue and global market share of Central Nervous System Drugs from 2019 to 2022.
Chapter 3, the Central Nervous System Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Central Nervous System Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Central Nervous System Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Central Nervous System Drugs.
Chapter 13, 14, and 15, to describe Central Nervous System Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Central Nervous System Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Central Nervous System Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 OTC
1.2.3 Rx Drugs
1.3 Market Analysis by Application
1.3.1 Overview: Global Central Nervous System Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Central Nervous System Drugs Market Size & Forecast
1.4.1 Global Central Nervous System Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Central Nervous System Drugs Sales in Volume (2017-2028)
1.4.3 Global Central Nervous System Drugs Price (2017-2028)
1.5 Global Central Nervous System Drugs Production Capacity Analysis
1.5.1 Global Central Nervous System Drugs Total Production Capacity (2017-2028)
1.5.2 Global Central Nervous System Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Central Nervous System Drugs Market Drivers
1.6.2 Central Nervous System Drugs Market Restraints
1.6.3 Central Nervous System Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Central Nervous System Drugs Product and Services
2.1.4 Biogen Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Central Nervous System Drugs Product and Services
2.2.4 Pfizer Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Teva
2.3.1 Teva Details
2.3.2 Teva Major Business
2.3.3 Teva Central Nervous System Drugs Product and Services
2.3.4 Teva Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Central Nervous System Drugs Product and Services
2.4.4 Novartis Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Central Nervous System Drugs Product and Services
2.5.4 Johnson & Johnson Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 EliLilly
2.6.1 EliLilly Details
2.6.2 EliLilly Major Business
2.6.3 EliLilly Central Nervous System Drugs Product and Services
2.6.4 EliLilly Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Otsuka
2.7.1 Otsuka Details
2.7.2 Otsuka Major Business
2.7.3 Otsuka Central Nervous System Drugs Product and Services
2.7.4 Otsuka Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Central Nervous System Drugs Product and Services
2.8.4 Merck Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 AstraZeneca
2.9.1 AstraZeneca Details
2.9.2 AstraZeneca Major Business
2.9.3 AstraZeneca Central Nervous System Drugs Product and Services
2.9.4 AstraZeneca Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Central Nervous System Drugs Product and Services
2.10.4 Novartis Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Takeda
2.11.1 Takeda Details
2.11.2 Takeda Major Business
2.11.3 Takeda Central Nervous System Drugs Product and Services
2.11.4 Takeda Central Nervous System Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Central Nervous System Drugs Breakdown Data by Manufacturer
3.1 Global Central Nervous System Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Central Nervous System Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Central Nervous System Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Central Nervous System Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Central Nervous System Drugs Manufacturer Market Share in 2021
3.5 Global Central Nervous System Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Central Nervous System Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Central Nervous System Drugs Market Size by Region
4.1.1 Global Central Nervous System Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Central Nervous System Drugs Revenue by Region (2017-2028)
4.2 North America Central Nervous System Drugs Revenue (2017-2028)
4.3 Europe Central Nervous System Drugs Revenue (2017-2028)
4.4 Asia-Pacific Central Nervous System Drugs Revenue (2017-2028)
4.5 South America Central Nervous System Drugs Revenue (2017-2028)
4.6 Middle East and Africa Central Nervous System Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Central Nervous System Drugs Sales in Volume by Type (2017-2028)
5.2 Global Central Nervous System Drugs Revenue by Type (2017-2028)
5.3 Global Central Nervous System Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Central Nervous System Drugs Sales in Volume by Application (2017-2028)
6.2 Global Central Nervous System Drugs Revenue by Application (2017-2028)
6.3 Global Central Nervous System Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Central Nervous System Drugs Sales by Type (2017-2028)
7.2 North America Central Nervous System Drugs Sales by Application (2017-2028)
7.3 North America Central Nervous System Drugs Market Size by Country
7.3.1 North America Central Nervous System Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Central Nervous System Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Central Nervous System Drugs Sales by Type (2017-2028)
8.2 Europe Central Nervous System Drugs Sales by Application (2017-2028)
8.3 Europe Central Nervous System Drugs Market Size by Country
8.3.1 Europe Central Nervous System Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Central Nervous System Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Central Nervous System Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Central Nervous System Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Central Nervous System Drugs Market Size by Region
9.3.1 Asia-Pacific Central Nervous System Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Central Nervous System Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Central Nervous System Drugs Sales by Type (2017-2028)
10.2 South America Central Nervous System Drugs Sales by Application (2017-2028)
10.3 South America Central Nervous System Drugs Market Size by Country
10.3.1 South America Central Nervous System Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Central Nervous System Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Central Nervous System Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Central Nervous System Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Central Nervous System Drugs Market Size by Country
11.3.1 Middle East & Africa Central Nervous System Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Central Nervous System Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Central Nervous System Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Central Nervous System Drugs
12.3 Central Nervous System Drugs Production Process
12.4 Central Nervous System Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Central Nervous System Drugs Typical Distributors
13.3 Central Nervous System Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Central Nervous System Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Central Nervous System Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Biogen Basic Information, Manufacturing Base and Competitors
Table 4. Biogen Major Business
Table 5. Biogen Central Nervous System Drugs Product and Services
Table 6. Biogen Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Major Business
Table 9. Pfizer Central Nervous System Drugs Product and Services
Table 10. Pfizer Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Teva Basic Information, Manufacturing Base and Competitors
Table 12. Teva Major Business
Table 13. Teva Central Nervous System Drugs Product and Services
Table 14. Teva Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Novartis Basic Information, Manufacturing Base and Competitors
Table 16. Novartis Major Business
Table 17. Novartis Central Nervous System Drugs Product and Services
Table 18. Novartis Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 20. Johnson & Johnson Major Business
Table 21. Johnson & Johnson Central Nervous System Drugs Product and Services
Table 22. Johnson & Johnson Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. EliLilly Basic Information, Manufacturing Base and Competitors
Table 24. EliLilly Major Business
Table 25. EliLilly Central Nervous System Drugs Product and Services
Table 26. EliLilly Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Otsuka Basic Information, Manufacturing Base and Competitors
Table 28. Otsuka Major Business
Table 29. Otsuka Central Nervous System Drugs Product and Services
Table 30. Otsuka Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Merck Basic Information, Manufacturing Base and Competitors
Table 32. Merck Major Business
Table 33. Merck Central Nervous System Drugs Product and Services
Table 34. Merck Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 36. AstraZeneca Major Business
Table 37. AstraZeneca Central Nervous System Drugs Product and Services
Table 38. AstraZeneca Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Novartis Basic Information, Manufacturing Base and Competitors
Table 40. Novartis Major Business
Table 41. Novartis Central Nervous System Drugs Product and Services
Table 42. Novartis Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Takeda Basic Information, Manufacturing Base and Competitors
Table 44. Takeda Major Business
Table 45. Takeda Central Nervous System Drugs Product and Services
Table 46. Takeda Central Nervous System Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Global Central Nervous System Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 48. Global Central Nervous System Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 49. Market Position of Manufacturers in Central Nervous System Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 50. Global Central Nervous System Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 51. Head Office and Central Nervous System Drugs Production Site of Key Manufacturer
Table 52. Central Nervous System Drugs New Entrant and Capacity Expansion Plans
Table 53. Central Nervous System Drugs Mergers & Acquisitions in the Past Five Years
Table 54. Global Central Nervous System Drugs Sales by Region (2017-2022) & (K Units)
Table 55. Global Central Nervous System Drugs Sales by Region (2023-2028) & (K Units)
Table 56. Global Central Nervous System Drugs Revenue by Region (2017-2022) & (USD Million)
Table 57. Global Central Nervous System Drugs Revenue by Region (2023-2028) & (USD Million)
Table 58. Global Central Nervous System Drugs Sales by Type (2017-2022) & (K Units)
Table 59. Global Central Nervous System Drugs Sales by Type (2023-2028) & (K Units)
Table 60. Global Central Nervous System Drugs Revenue by Type (2017-2022) & (USD Million)
Table 61. Global Central Nervous System Drugs Revenue by Type (2023-2028) & (USD Million)
Table 62. Global Central Nervous System Drugs Price by Type (2017-2022) & (USD/Unit)
Table 63. Global Central Nervous System Drugs Price by Type (2023-2028) & (USD/Unit)
Table 64. Global Central Nervous System Drugs Sales by Application (2017-2022) & (K Units)
Table 65. Global Central Nervous System Drugs Sales by Application (2023-2028) & (K Units)
Table 66. Global Central Nervous System Drugs Revenue by Application (2017-2022) & (USD Million)
Table 67. Global Central Nervous System Drugs Revenue by Application (2023-2028) & (USD Million)
Table 68. Global Central Nervous System Drugs Price by Application (2017-2022) & (USD/Unit)
Table 69. Global Central Nervous System Drugs Price by Application (2023-2028) & (USD/Unit)
Table 70. North America Central Nervous System Drugs Sales by Country (2017-2022) & (K Units)
Table 71. North America Central Nervous System Drugs Sales by Country (2023-2028) & (K Units)
Table 72. North America Central Nervous System Drugs Revenue by Country (2017-2022) & (USD Million)
Table 73. North America Central Nervous System Drugs Revenue by Country (2023-2028) & (USD Million)
Table 74. North America Central Nervous System Drugs Sales by Type (2017-2022) & (K Units)
Table 75. North America Central Nervous System Drugs Sales by Type (2023-2028) & (K Units)
Table 76. North America Central Nervous System Drugs Sales by Application (2017-2022) & (K Units)
Table 77. North America Central Nervous System Drugs Sales by Application (2023-2028) & (K Units)
Table 78. Europe Central Nervous System Drugs Sales by Country (2017-2022) & (K Units)
Table 79. Europe Central Nervous System Drugs Sales by Country (2023-2028) & (K Units)
Table 80. Europe Central Nervous System Drugs Revenue by Country (2017-2022) & (USD Million)
Table 81. Europe Central Nervous System Drugs Revenue by Country (2023-2028) & (USD Million)
Table 82. Europe Central Nervous System Drugs Sales by Type (2017-2022) & (K Units)
Table 83. Europe Central Nervous System Drugs Sales by Type (2023-2028) & (K Units)
Table 84. Europe Central Nervous System Drugs Sales by Application (2017-2022) & (K Units)
Table 85. Europe Central Nervous System Drugs Sales by Application (2023-2028) & (K Units)
Table 86. Asia-Pacific Central Nervous System Drugs Sales by Region (2017-2022) & (K Units)
Table 87. Asia-Pacific Central Nervous System Drugs Sales by Region (2023-2028) & (K Units)
Table 88. Asia-Pacific Central Nervous System Drugs Revenue by Region (2017-2022) & (USD Million)
Table 89. Asia-Pacific Central Nervous System Drugs Revenue by Region (2023-2028) & (USD Million)
Table 90. Asia-Pacific Central Nervous System Drugs Sales by Type (2017-2022) & (K Units)
Table 91. Asia-Pacific Central Nervous System Drugs Sales by Type (2023-2028) & (K Units)
Table 92. Asia-Pacific Central Nervous System Drugs Sales by Application (2017-2022) & (K Units)
Table 93. Asia-Pacific Central Nervous System Drugs Sales by Application (2023-2028) & (K Units)
Table 94. South America Central Nervous System Drugs Sales by Country (2017-2022) & (K Units)
Table 95. South America Central Nervous System Drugs Sales by Country (2023-2028) & (K Units)
Table 96. South America Central Nervous System Drugs Revenue by Country (2017-2022) & (USD Million)
Table 97. South America Central Nervous System Drugs Revenue by Country (2023-2028) & (USD Million)
Table 98. South America Central Nervous System Drugs Sales by Type (2017-2022) & (K Units)
Table 99. South America Central Nervous System Drugs Sales by Type (2023-2028) & (K Units)
Table 100. South America Central Nervous System Drugs Sales by Application (2017-2022) & (K Units)
Table 101. South America Central Nervous System Drugs Sales by Application (2023-2028) & (K Units)
Table 102. Middle East & Africa Central Nervous System Drugs Sales by Region (2017-2022) & (K Units)
Table 103. Middle East & Africa Central Nervous System Drugs Sales by Region (2023-2028) & (K Units)
Table 104. Middle East & Africa Central Nervous System Drugs Revenue by Region (2017-2022) & (USD Million)
Table 105. Middle East & Africa Central Nervous System Drugs Revenue by Region (2023-2028) & (USD Million)
Table 106. Middle East & Africa Central Nervous System Drugs Sales by Type (2017-2022) & (K Units)
Table 107. Middle East & Africa Central Nervous System Drugs Sales by Type (2023-2028) & (K Units)
Table 108. Middle East & Africa Central Nervous System Drugs Sales by Application (2017-2022) & (K Units)
Table 109. Middle East & Africa Central Nervous System Drugs Sales by Application (2023-2028) & (K Units)
Table 110. Central Nervous System Drugs Raw Material
Table 111. Key Manufacturers of Central Nervous System Drugs Raw Materials
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Central Nervous System Drugs Typical Distributors
Table 115. Central Nervous System Drugs Typical Customers
List of Figures
Figure 1. Central Nervous System Drugs Picture
Figure 2. Global Central Nervous System Drugs Revenue Market Share by Type in 2021
Figure 3. OTC
Figure 4. Rx Drugs
Figure 5. Global Central Nervous System Drugs Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Retail Pharmacy
Figure 8. Global Central Nervous System Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Central Nervous System Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Central Nervous System Drugs Sales (2017-2028) & (K Units)
Figure 11. Global Central Nervous System Drugs Price (2017-2028) & (USD/Unit)
Figure 12. Global Central Nervous System Drugs Production Capacity (2017-2028) & (K Units)
Figure 13. Global Central Nervous System Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Central Nervous System Drugs Market Drivers
Figure 15. Central Nervous System Drugs Market Restraints
Figure 16. Central Nervous System Drugs Market Trends
Figure 17. Global Central Nervous System Drugs Sales Market Share by Manufacturer in 2021
Figure 18. Global Central Nervous System Drugs Revenue Market Share by Manufacturer in 2021
Figure 19. Central Nervous System Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Central Nervous System Drugs Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Central Nervous System Drugs Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Central Nervous System Drugs Sales Market Share by Region (2017-2028)
Figure 23. Global Central Nervous System Drugs Revenue Market Share by Region (2017-2028)
Figure 24. North America Central Nervous System Drugs Revenue (2017-2028) & (USD Million)
Figure 25. Europe Central Nervous System Drugs Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Central Nervous System Drugs Revenue (2017-2028) & (USD Million)
Figure 27. South America Central Nervous System Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Central Nervous System Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Global Central Nervous System Drugs Sales Market Share by Type (2017-2028)
Figure 30. Global Central Nervous System Drugs Revenue Market Share by Type (2017-2028)
Figure 31. Global Central Nervous System Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Central Nervous System Drugs Sales Market Share by Application (2017-2028)
Figure 33. Global Central Nervous System Drugs Revenue Market Share by Application (2017-2028)
Figure 34. Global Central Nervous System Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Central Nervous System Drugs Sales Market Share by Type (2017-2028)
Figure 36. North America Central Nervous System Drugs Sales Market Share by Application (2017-2028)
Figure 37. North America Central Nervous System Drugs Sales Market Share by Country (2017-2028)
Figure 38. North America Central Nervous System Drugs Revenue Market Share by Country (2017-2028)
Figure 39. United States Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Central Nervous System Drugs Sales Market Share by Type (2017-2028)
Figure 43. Europe Central Nervous System Drugs Sales Market Share by Application (2017-2028)
Figure 44. Europe Central Nervous System Drugs Sales Market Share by Country (2017-2028)
Figure 45. Europe Central Nervous System Drugs Revenue Market Share by Country (2017-2028)
Figure 46. Germany Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Central Nervous System Drugs Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Central Nervous System Drugs Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Central Nervous System Drugs Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Central Nervous System Drugs Revenue Market Share by Region (2017-2028)
Figure 55. China Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Central Nervous System Drugs Sales Market Share by Type (2017-2028)
Figure 62. South America Central Nervous System Drugs Sales Market Share by Application (2017-2028)
Figure 63. South America Central Nervous System Drugs Sales Market Share by Country (2017-2028)
Figure 64. South America Central Nervous System Drugs Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Central Nervous System Drugs Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Central Nervous System Drugs Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Central Nervous System Drugs Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Central Nervous System Drugs Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Central Nervous System Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Central Nervous System Drugs in 2021
Figure 76. Manufacturing Process Analysis of Central Nervous System Drugs
Figure 77. Central Nervous System Drugs Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
| 【中枢神経系用治療薬について】 中枢神経系用治療薬は、脳や脊髄などの中枢神経系に作用し、さまざまな神経疾患の治療や症状緩和を目的とした薬剤の総称です。これらの薬は、精神的な疾患や神経系の障害を持つ患者さんに対して重要な役割を果たします。ここでは、中枢神経系用治療薬の定義、特徴、種類、用途、関連技術などについて詳しく説明いたします。 中枢神経系用治療薬の定義は、主に脳および脊髄に作用することで、神経伝達物質の調節や、神経回路の機能を改善することを目的とした薬剤として位置付けられます。これにより、さまざまな神経系の異常や病気の治療が可能になります。 中枢神経系用治療薬の特徴として、まず第一にそれぞれの薬剤が特異的に作用する神経伝達物質に着目することが挙げられます。たとえば、抗うつ薬はセロトニンやノルエピネフリンなどの神経伝達物質を調整することで、気分障害を改善します。また、抗精神病薬はドパミンの作用を抑えることによって、統合失調症などの症状を軽減します。さらに、抗てんかん薬は、神経の過剰興奮を抑制することにより、発作を予防する役割を果たします。 次に、中枢神経系用治療薬にはさまざまな種類があります。主な分類として、抗うつ薬、抗精神病薬、抗てんかん薬、鎮痛薬、抗パーキンソン病薬、睡眠薬などが挙げられます。それぞれの薬剤は異なる作用機序を持ち、特定の症状や疾患に応じて使用されます。 抗うつ薬は、主にうつ病や不安障害の治療に用いられます。代表的なものとして、選択的セロトニン再取り込み阻害薬（SSRI）や三環系抗うつ薬があります。これらは、神経伝達物質のバランスを調整することで、気分を安定させる作用があります。 抗精神病薬は、主に統合失調症や双極性障害などの精神疾患の治療に使用されます。第一世代の抗精神病薬（典型的抗精神病薬）は、主にドパミンのM2受容体をブロックすることで、陽性症状を改善します。一方、第二世代の抗精神病薬（非典型的抗精神病薬）は、ドパミンだけでなくセロトニン系の神経伝達物質にも作用し、陰性症状や感情症状にも効果を示します。 抗てんかん薬は、てんかん発作の予防や治療に用いられます。これには、カルバマゼピン、バルプロ酸、レベチラセタムなどが含まれます。これらの薬は神経の過剰興奮を抑える作用があり、発作の発生を防ぎます。 鎮痛薬は、痛みの緩和を目的とした薬剤であり、オピオイド系や非オピオイド系の薬が含まれます。これらは、脳での痛みの認識を抑制することによって鎮痛作用を示します。 抗パーキンソン病薬は、パーキンソン病の症状を改善するために使用されます。これには、ドパミン前駆物質であるレボドパや、ドパミン受容体刺激薬が含まれます。これらの薬はドパミンの作用を補完することで、運動機能を改善します。 睡眠薬は、不眠症などの治療に使用されます。これには、ベンゾジアゼピン系薬剤や非ベンゾジアゼピン系薬剤が含まれ、脳内の神経活動を抑えることで睡眠を誘導します。 中枢神経系用治療薬の用途は非常に多岐にわたります。うつ病、統合失調症、不安障害、てんかん、パーキンソン病、疼痛管理、睡眠障害など、さまざまな疾患に対して治療効果を発揮します。また、これらの薬剤はしばしば併用療法として使用されることも多く、個々の患者の症状や反応に応じた治療が求められます。 中枢神経系用治療薬の関連技術としては、創薬技術や薬物送達システムが挙げられます。新しい薬剤の開発には、分子生物学や遺伝子操作技術が大いに役立っています。また、脳に薬剤を届けるためのナノ粒子技術や、経鼻投与、経皮投与などの非侵襲的な方法も研究されています。これにより、より的確な方法で薬剤を脳に届け、副作用を低減することが期待されています。 さらに、近年ではバイオマーカーの研究も進んでおり、個々の患者に適した治療法の選択を可能にするための指標として活用されることが期待されています。これにより、より精度の高いパーソナライズド医療が実現し、中枢神経系用治療薬の効果を最大限に引き出すことができるでしょう。 中枢神経系用治療薬は、患者の生活の質を向上させるために不可欠な要素です。しかし、個々の薬剤には副作用や依存症のリスクも伴います。そのため、医療従事者は患者に対して適切な情報提供を行い、治療のメリットとデメリットを十分に理解させることが重要です。また、効果的な薬の使用だけでなく、生活習慣の改善や心理的サポートも併せて行うことで、より良い治療成績を上げることが期待されています。 以上のように、中枢神経系用治療薬は、現代医学において極めて重要な役割を担っています。今後も研究が進み、より効果的で安全な治療薬が開発されることが期待されます。これにより、神経系の様々な疾患に苦しむ患者さんの支えとなり、治療可能な道筋を提供することができるでしょう。 |
• 日本語訳：中枢神経系用治療薬のグローバル市場2022年
• レポートコード：GIR-23F3772 ▷ お問い合わせ（見積依頼・ご注文・質問）